Since ATRX loss of function and MYCN amplification are reported to be mutually exclusive [42], and 11q deletion is very rarely observed in MYCN-amplified tumours, we propose PARP and ATR inhibitors may be beneficial to a large subset of high-risk NB patients. The gene discussed is MYCN; the disease is neuroblastoma.